Società | Nome | Borsa | Settore | Industria | Capitalizzazione di mercato | Rapporto Prezzo/Utile | Rapporto PEG | Ultimo prezzo di scambio | Variazione giornaliera (%) | Fair Value | Rialzo Fair Value | Etichetta Fair Value | Price Target (analisti) | Rialzo target analisti | Salute complessiva |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sun Pharma Advanced Research | BSE | Salute | Prodotti farmaceutici | 4,34 Bln INR | 39,2x | 1,33 | 1.805,75 INR | -1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 14,5% Rialzo | Fai l’upgrade a Pro+ | |
Sun Pharma AR | NSE | Salute | Prodotti farmaceutici | 4,34 Bln INR | 39,2x | 1,33 | 1.808,85 INR | -0,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 14,8% Rialzo | Fai l’upgrade a Pro+ | |
Divis Laboratories | NSE | Salute | Prodotti farmaceutici | 1,55 Bln INR | 85,4x | 2,24 | 5.846,75 INR | 0,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -3,3% Ribasso | Fai l’upgrade a Pro+ | |
Divis Laboratories | BSE | Salute | Prodotti farmaceutici | 1,55 Bln INR | 85,4x | 2,24 | 5.833,60 INR | 0,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -3,3% Ribasso | Fai l’upgrade a Pro+ | |
Cipla | BSE | Salute | Prodotti farmaceutici | 1,19 Bln INR | 26,7x | 0,88 | 1.471,90 INR | -2,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 10,6% Rialzo | Fai l’upgrade a Pro+ | |
Cipla | NSE | Salute | Prodotti farmaceutici | 1,19 Bln INR | 26,7x | 0,88 | 1.472,05 INR | -2,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 10,7% Rialzo | Fai l’upgrade a Pro+ | |
Torrent Pharmaceuticals | NSE | Salute | Prodotti farmaceutici | 1,16 Bln INR | 65,2x | 1,84 | 3.437 INR | -0,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 4,4% Rialzo | Fai l’upgrade a Pro+ | |
Torrent Pharmaceuticals | BSE | Salute | Prodotti farmaceutici | 1,16 Bln INR | 65,2x | 1,84 | 3.443,45 INR | -0,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 4,5% Rialzo | Fai l’upgrade a Pro+ | |
Mankind Pharma | BSE | Salute | Prodotti farmaceutici | 1,16 Bln INR | 53,2x | 1,4 | 2.819,95 INR | -2,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -0,4% Ribasso | Fai l’upgrade a Pro+ | |
Mankind Pharma | NSE | Salute | Prodotti farmaceutici | 1,16 Bln INR | 53,2x | 1,4 | 2.805,20 INR | -3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -0,5% Ribasso | Fai l’upgrade a Pro+ | |
Dr Reddy’s Laboratories | BSE | Salute | Prodotti farmaceutici | 1,12 Bln INR | 21,2x | 4,2 | 1.347,80 INR | 1,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 0,7% Rialzo | Fai l’upgrade a Pro+ | |
Dr Reddy’s Laboratories | NSE | Salute | Prodotti farmaceutici | 1,12 Bln INR | 21,2x | 4,2 | 1.343,65 INR | 1,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 0,7% Rialzo | Fai l’upgrade a Pro+ | |
Lupin | BSE | Salute | Prodotti farmaceutici | 981,14 Mrd INR | 37,6x | 0,37 | 2.137,95 INR | -1,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 5% Rialzo | Fai l’upgrade a Pro+ | |
Lupin | NSE | Salute | Prodotti farmaceutici | 981,14 Mrd INR | 37,6x | 0,37 | 2.150,70 INR | -0,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 4,4% Rialzo | Fai l’upgrade a Pro+ | |
Zydus Lifesciences | BSE | Salute | Prodotti farmaceutici | 978,41 Mrd INR | 23x | 0,43 | 972 INR | -1,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 10,6% Rialzo | Fai l’upgrade a Pro+ | |
Zydus Lifesciences | NSE | Salute | Prodotti farmaceutici | 978,41 Mrd INR | 23x | 0,43 | 973,50 INR | -1,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 10,6% Rialzo | Fai l’upgrade a Pro+ | |
Aurobindo Pharma | BSE | Salute | Prodotti farmaceutici | 718,60 Mrd INR | 20,5x | 0,36 | 1.246 INR | -0,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 23,1% Rialzo | Fai l’upgrade a Pro+ | |
Aurobindo Pharma | NSE | Salute | Prodotti farmaceutici | 718,60 Mrd INR | 20,5x | 0,36 | 1.241,70 INR | -1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 23,1% Rialzo | Fai l’upgrade a Pro+ | |
Alkem Laboratories Ltd BO | BSE | Salute | Prodotti farmaceutici | 647,54 Mrd INR | 31x | 0,63 | 5.440,20 INR | -1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 10,9% Rialzo | Fai l’upgrade a Pro+ | |
Alkem Laboratories Ltd | NSE | Salute | Prodotti farmaceutici | 647,54 Mrd INR | 31x | 0,63 | 5.427,50 INR | -1,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 11% Rialzo | Fai l’upgrade a Pro+ | |
Abbott India Ltd | BSE | Salute | Prodotti farmaceutici | 607,96 Mrd INR | 47,6x | 2,52 | 28.601 INR | -1,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 6,7% Rialzo | Fai l’upgrade a Pro+ | |
Abbott India Ltd | NSE | Salute | Prodotti farmaceutici | 607,96 Mrd INR | 47,6x | 2,52 | 28.655,35 INR | -1,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 6,7% Rialzo | Fai l’upgrade a Pro+ | |
Glenmark Pharmaceuticals | BSE | Salute | Prodotti farmaceutici | 435,57 Mrd INR | -49,9x | 0,05 | 1.548,25 INR | 0,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 9,3% Rialzo | Fai l’upgrade a Pro+ | |
Glenmark Pharmaceuticals | NSE | Salute | Prodotti farmaceutici | 435,57 Mrd INR | -49,9x | 0,05 | 1.541,65 INR | 0,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 9,2% Rialzo | Fai l’upgrade a Pro+ | |
IPCA Laboratories | BSE | Salute | Prodotti farmaceutici | 401,52 Mrd INR | 61,1x | 1,72 | 1.600 INR | 0,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 7% Rialzo | Fai l’upgrade a Pro+ | |
IPCA Laboratories | NSE | Salute | Prodotti farmaceutici | 401,52 Mrd INR | 61,1x | 1,72 | 1.582,50 INR | -0,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 6,9% Rialzo | Fai l’upgrade a Pro+ | |
GSK Pharmaceuticals | NSE | Salute | Prodotti farmaceutici | 383,88 Mrd INR | 58x | 9,1 | 2.275,95 INR | -2,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 25,9% Rialzo | Fai l’upgrade a Pro+ | |
GSK Pharmaceuticals | BSE | Salute | Prodotti farmaceutici | 383,88 Mrd INR | 58x | 9,1 | 2.272 INR | -2,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 26% Rialzo | Fai l’upgrade a Pro+ | |
Ajanta Pharma Ltd | NSE | Salute | Prodotti farmaceutici | 356,60 Mrd INR | 41,6x | 1,18 | 2.866,45 INR | -0,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 12,7% Rialzo | Fai l’upgrade a Pro+ | |
Ajanta Pharma Ltd-BO | BSE | Salute | Prodotti farmaceutici | 356,60 Mrd INR | 41,6x | 1,18 | 2.841 INR | -1,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 12,6% Rialzo | Fai l’upgrade a Pro+ |